Jpn. J. Infect. Dis., 65 (4), 301-305, 2012
To see a printable version of the article in the Adobe file format, click this [PDF] link.
Atsuko Noguchi1, Toyoko Nakagomi2, Shigeru Kimura3, Yoshihiro Takahashi4, Kenichi Matsuno5, Hiromi Koizumi6, Arata Watanabe7, Hiroo Noguchi8, Tadahiko Ito9, Mihoko Ohtsuka10, Naoya Uemura11, Osamu Takeda12, Akira Komatsu13, Wataru Kikuchi14, Masaki Komatsu15, Hiroshi Fukaya16, Shinobu Miura17, Hiroyuki Toda18, Osamu Nakagomi2*, and Tsutomu Takahashi1
1Department of Pediatrics, Akita University Graduate School of Medicine, Akita 010-8543; 2Division of Molecular Epidemiology, Graduate School of Biomedical Sciences, and Global Center of Excellence, Nagasaki University, Nagasaki 852-8523; 3Akita Red Cross Hospital, Akita 010-1495; 4Odate Municipal Hospital, Odate 017-8550; 5Oga Minato Municipal Hospital, Oga 010-0511; 6Akita City Hospital, Akita 010-0933; 7Nakadori General Hospital, Akita 010-8577; 8Kita-Akita Municipal Hospital, Kitaakita 018-4221; 9Hiraka General Hospital, Yokote 013-8610; 10Akita Social Insurance Hospital, Noshiro 016-0851; 11Yamamoto-Kumiai General Hospital, Noshiro 016-0014; 12Koto General Hospital, Hachirogata 018-1605; 13Yokote Municipal Hospital, Yokote 013-8602; 14Ogachi Central Hospital, Yuzawa 012-0055; 15Akita-Kumiai General Hospital, Akita 011-0948; 16Senboku-Kumiai General Hospital, Daisen 014-0027; 17Yuri-Kumiai General Hospital, Yurihonjo 015-8511; and 18Kazuno-Kosei Hospital, Kazuno 018-5201, Japan
(Received February 27, 2012. Accepted May 15, 2012)
*Corresponding author: Mailing address: Division of Molecular Epidemiology, Graduate School of Biomedical Sciences, and Global Center of Excellence, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. Tel: +81 95 819 7063, Fax: +81 95 819 7064, E-mail: このメールアドレスはスパムボットから保護されています。閲覧するにはJavaScriptを有効にする必要があります。
SUMMARY: One concern about rotavirus vaccines is its possible association with intussusception. Thus, it is necessary to determine the baseline incidence for intussusception in the first year of life in places where rotavirus vaccines are introduced. However, few safety data exist for the period at which the first dose of Rotarix and RotaTeq are allowed to administer in Japan. The first dose of Rotarix is scheduled to administer at 6–20 weeks of age and that of RotaTeq is scheduled to administer at 6–24 weeks of age; the upper limits for these vaccines is later than the upper limit recommended by the World Health Organization by 5 and 9 weeks, respectively. We performed a retrospective cross-sectional study by reviewing medical charts of all hospitals that provided pediatric beds in Akita Prefecture, Japan, and identifying the cases of intussusception that met the Brighton criteria level 1 in these hospitals between January 2001 and December 2010. During this 10-year period, 122 children younger than 1 year of age were diagnosed with intussusception. The incidence of intussusception was estimated at 158 per 100,000 person-years among children younger than 1 year (95% confidence interval, 131–188), 10 per 100,000 person-years for children aged 0–2 months, 165 for children aged 3–5 months, and 300 for children aged 6–8 months. This rapid and substantial increase in the incidence of intussusception during the first year of life should be considered when formulating the immunization schedule for administering rotavirus vaccines in Japan.
